Abstract
Objective To explore the value of the combination of serum levels of AFP, GP73, and CA125 in diagnosis of malignant tumors of digestive system. Methods 100 patients with malignant tumors of digestive system treated at our hospital from March, 2015 to March, 2017 were set as a malignancy group, 98 patients with benign tumors a benign group, and 100 healthy objects taking physical examination a control group. The serum levels of AFP, GP73, and CA125 were detected. The area under curve (AUC) of Receiver Operating Characteristic(ROC), sensitivity, specificity, and accuracy of the combination of AFP, GP73, and CA125 in the diagnosis of malignant tumors of digestive system were analyzed. Results The levels of AFP, GP73, and CA125 were (144.91±30.54) mg/L, (92.87±13.25) mg/ml, and (166.05±30.29) U/ml in the malignancy group, which were significantly higher than those in the benign group and the control group (P<0.05). The AUC of AFP, GP73, and CA125 in the diagnosis of malignant tumors were 0.701, 0.725, and 0.669,(P<0.05), respectively. The area under the ROC curve of the combinations of GP73+CA125, GP73+AFP, and GP73+CA125+AFP were 0.752, 0.726, and 0.921, respectively. Conclusion Combination of serum levels of AFP, GP73, and CA125 in the diagnosis of malignant tumors of digestive system can improve the specificity and accuracy of early diagnosis and has early predictive value. Key words: AFP; GP73; CA125; Malignant tumors of digestive system
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call